¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ 44th Korean College of Rheumatolgy Annual Scientific Meeting and the 18th International Symposium (KCR2024)-ù°³¯ : 2024-05-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ 44th Korean College of Rheumatolgy Annual Scientific Meeting and the 18th International Symposium (KCR2024)-ù°³¯ : 2024-05-16
±³À°ÀÏÀÚ : 2024-05-16
±³À°Àå¼Ò : ÄÜ·¡µå ¼­¿ï, ¿Â¶óÀÎ ¿þºñ³ª

±³À°ÁÖÁ¦ : (¿Â.¿ÀÇÁ º´Çà) 44th Korean College of Rheumatolgy Annual Scientific Meeting and the 18th International Symposium (KCR2024)-ù°³¯

ÁÖÃÖ±â°ü : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
´ã´çÀÚ : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ
¿¬¶ôó : 02-794-2630  

À̸ÞÀÏ : webmaster@rheum.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, ¿µ»óÀÇÇаú, ÀçÈ°ÀÇÇаú, °¡Á¤ÀÇÇаú

Âü¼®¿¹»óÀÎ : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 16 ½Ã°£ 50ºÐ

¼¼ºÎ¼ö°­·á : 250,000¿ø  

ºñ°í »çÀüµî·Ï ȸ¿ø Àü¹®ÀÇ ÀüÀÓÀÇ 180,000¿ø, ºñȸ¿ø Àü¹®ÀÇ ÀüÀÓÀÇ 230,000¿øÇöÀåµî·Ï ȸ¿ø Àü¹®ÀÇ ÀüÀÓÀÇ 200,000¿ø, ºñȸ¿ø Àü¹®ÀÇ ÀüÀÓÀÇ 250,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 09:00~09:30 My Journey with Rheumatology ÃÖÁ¤À±(´ë±¸°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 09:30~10:00 The Future of Korean Rheumatology ÀüÀç¹ü(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 10:30~11:00 Advancing Rheumatic Care: Recent Updates in Biologics and Targeted DMARDs of Spondyloarthritis ÀÌ»óÈÆ(°æÈñ´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 11:00~11:30 Gout and Beyond: Crystal Induced Arthritis Update Á¤ÀçÇö(°í·Á´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 11:30~12:00 Exploring the Uncommon: Updates on Rare Rheumatic Diseases ÀÌâÈÆ(¿ø±¤´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 12:00~12:40 Roles of Filgotinib in Treatment Strategy of RA: Japanese Experience and Perspective Kei Ikeda(Dokkyo Medical Univ., Japan)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 13:00~13:30 SLE Heterogeneity: Lessons from Immune Monitoring Patients Virginia Pascual(Weill Cornell Medicine, USA)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 13:30~14:00 Immunopathogenic Role of Type I Inteferon in Lupus °û½Â±â(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 14:00~14:30 Metabolism of autoantibody production in lupus Laurence Morel(UT Health San Antonio, USA)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 15:30~16:00 Upgrading the Design of Clinical Trials toward Tailored Medicine in Rheumatoid Arthritis Yuko Kaneko(Keio Univ., Japan)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 16:00~16:30 Unmet Needs in the Pharmacological Treatment of Rheumatoid Arthritis ÀÌÇý¼ø(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 16:30~17:00 Lessons from Chinese Rheumatism Data Center-Myositis Registry, Prospective Registry Of Myositis  (CRDC-MYO/PROMIS) . Qian Wang(Peking Union Medical College Hosp., China)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 1 17:00~17:30 Clinical Implication of Myositis-specific Autoantibodies in Idiopathic Inflammatory Myopathies ±èÁøÇö(Ãæ³²´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 10:30~11:00 Stem Cell: What They Are and What They Do (Regenerative Medicine) ÁÖÁöÇö(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 11:00~11:30 Current Immunopathogenesis of Spondyloarthritis ±èÅÂÁ¾(Àü³²´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 11:30~12:00 Recent Advances in Understanding the Genetic Architecture ¹æ¼Ò¿µ(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 12:00~12:40 Infliximab SC: A New Therapeutic Option in Rheumatic Disease ÀÌ¿¬¾Æ(°æÈñ´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 13:00~13:30 Perioperative Inflammation 2BR02B in Rheumatoid Arthritis ½É½Âö(Ãæ³²´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 13:30~14:00 Orthopedic perspective on knee pain: pain evaluation, surgical timing, and patient care after TKA (especially in RA patients) ÀåÁ¾¹ü(¼­¿ï´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 14:00~14:30 Surgical Treatment for Foot and Ankle Problems in Rheumatoid Arthritis Á¤È«±Ù(°Ç±¹´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 15:30~15:40 (±¸¿¬ ¹ßÇ¥) Flare prediction after tapering the dose of tumor necrosis factor inhibitors in patients with axial spondyloarthritis: A nationwide cohort study ¿©Áö³ª(°¡Ãµ´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 15:40~15:50 (±¸¿¬ ¹ßÇ¥) Risk of spondyloarthritis in patients with inflammatory bowel disease under treatment with biologics or Janus Kinase inhibitors ±è¿µÀº(¿ï»ê´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 15:50~16:00 (±¸¿¬ ¹ßÇ¥) Performance of the 2021/2022 ASAS criteria for defining sacroiliitis/spondylitis in patients with psoriatic arthritis Xianfeng Yan(The Chinese Univ. of Hong Kong, Hong Kong)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 16:00~16:10 (±¸¿¬ ¹ßÇ¥) Dosage reduction of tumor necrosis factor inhibitors may have a negative effect on slowing early radiographic progression in patients with ankylosing spondylitis ±¸º»»ê(ÀÎÁ¦´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 16:10~16:20 (±¸¿¬ ¹ßÇ¥) Risk of cardiovascular disease associated with use of TNF-¥á inhibitor in ankylosing spondylitis ³²½Â¿Ï(¿¬¼¼´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 16:20~16:30 (±¸¿¬ ¹ßÇ¥) Artificial intelligence to predict disease activity using a multimodal model with magnetic resonance imaging and laboratory results in patients with axial spondyloarthritis À̽½±â(¼º±Õ°ü´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 16:30~16:40 (±¸¿¬ ¹ßÇ¥) Effect of monosodium urate on angiogenesis in gouty arthritis Ziyi Chen(Huashan Hosp., Fudan Univ., China)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 16:40~16:50 (±¸¿¬ ¹ßÇ¥) Long-term cardiovascular risk according to genetic risk for gout, lifestyle, and metabolic health: discovery and replication analysis of two diverse prospective cohorts ¹®±â¿ø(°­¿ø´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 16:50~17:00 (±¸¿¬ ¹ßÇ¥) Risk of gout among patients with tuberculosis: A nationwide cohort study in South Korea ¾È¼º¼ö(¿¬¼¼´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 2 17:30~18:10 Long-term Safety and Retention Rate of Tocilizumab °íÁ¤Èñ(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 12:00~12:40 Efficacy and Safety of Tacrolimus in the Treatment of RA Patients ¹Úµ¿Áø(Àü³²´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 13:00~13:10 (±¸¿¬ ¹ßÇ¥) Impact of prophylactic trimethoprim-sulfamethoxazole on the incidence of serious infection in patients with ANCA-associated vasculitis: A multicenter cohort study ±èÀ±±Ô(¼­¿ï´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 13:10~13:20 (±¸¿¬ ¹ßÇ¥) Progression to ANCA-associated vasculitis in patients with idiopathic interstitial pneumonia and positive ANCA results ÀÌ¿©Áø(¿ï»ê´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 13:20~13:30 (±¸¿¬ ¹ßÇ¥) Associative factors of pauci-immune glomerulonephritis in patients undergoing renal biopsy with positive ANCA results ÀÌ¿©Áø(¿ï»ê´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 13:30~13:40 (±¸¿¬ ¹ßÇ¥) Diagnosis of giant cell arteritis by 18F-FDG PET/CT in patients on corticosteroid treatment: Importance of delayed imaging Vincente Aldasoro caceres (Hosp. Universitario de Navarra, Spain)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 13:50~14:00 (±¸¿¬ ¹ßÇ¥) Population-based big data analysis on disease patterns in patients identified with juvenile idiopathic arthritis using national claims data Á¤´ëö(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 14:00~14:10 (±¸¿¬ ¹ßÇ¥) Diagnostic significance of early renal biomarkers (TGF b1, KIM-1) in children with juvenile idiopathic arthritis Svitlana Samsonenko(Dnipro State Medical Univ., Ukraine)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 14:10~14:20 (±¸¿¬ ¹ßÇ¥) Immune checkpoint molecule programmed death-ligand 1 (PD-L1) expression in paediatric vasculitides: A pilot study from Chandigarh, North India Pallavi Nadig(Postgraduate Institute of Medical Education and Research, Chandigarh, India)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 14:20~14:30 (±¸¿¬ ¹ßÇ¥) Pediatric uveitis continues to be a significant cause of ocular morbidity: Experience from 310 children at a single-centre in North India Prabal Barman(Post Graduate Institute of Medical Education and Research, Chandigarh, India)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 15:30~15:40 (±¸¿¬ ¹ßÇ¥) Integration of single-cell multi-omics profiling for investigating treatment response to tumor necrosis factor alpha inhibitors in patients with axial spondyloarthritis À̽½±â(¼º±Õ°ü´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 15:40~15:50 (±¸¿¬ ¹ßÇ¥) SREBP2 regulates osteoclast differentiation and protects mice from inflammatory bone loss ÃÖÀξÆ(ÃæºÏ´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 15:50~16:00 (±¸¿¬ ¹ßÇ¥) Serum lipidomic profiles identify potential diagnostic biomarker for seronegative rheumatoid arthritis versus hand osteoarthritis °íÁ¤Èñ(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 16:00~16:10 (±¸¿¬ ¹ßÇ¥) Deep learning-driven prediction of rheumatoid arthritis flare-ups using synovial biopsy transcriptomics Rifaldy Fajar(Karlstad Univ., Sweden)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 16:10~16:20 (±¸¿¬ ¹ßÇ¥) Potential of exosome-derived miRNA as a biomarker in adult-onset still ¾È¹ÌÇö(¾ÆÁÖ´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 16:30~16:40 (±¸¿¬ ¹ßÇ¥) Rebamipide attenuates renal manifestations via antioxidant effects on podocytes in an animal model for systemic lupus erythematosus ¹Ú¿ëÀç(°¡Å縯´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 16:40~16:50 (±¸¿¬ ¹ßÇ¥) Linc01150 promotes lymphatic infiltration in primary Sjogren Zhou Zhou (The First Affiliated Hosp. of USTC, Division of Life Sciences and Medicine, Univ. of Science, China)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 16:50~17:00 (±¸¿¬ ¹ßÇ¥) Dynamic immunophenotype of IgG4-Related disease: A longitudinal exploration with B cell depletion and multi-omics revelations ±èÈ¿Àç(Ä«À̽ºÆ®)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 17:00~17:10 (±¸¿¬ ¹ßÇ¥) Identification of novel role of osteoclast-derived DPP4 in fracture healing process À̽ÂÈÆ(ÇѾç´ëÇб³)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 17:10~17:20 (±¸¿¬ ¹ßÇ¥) Osteoarthritis drives inflammatory imprinting of synovial fibroblasts, exacerbating gouty arthritis through m6A modification modification of S100A4 Ziyi Chen(Huashan Hosp., Fudan Univ., China)

±³À°½Ã°£ 05¿ù 16ÀÏ Room 3 17:30~18:10 Treatment Landscape for Axial Spondyloarthritis in 2024 Sofia Ramiro(Leiden Univ. Medical Center, Netherlands)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ 44th Korean College of Rheumatolgy Annual Scientific Meeting and the 18th International Symposium (KCR2024)-ù°³¯ : 2024-05-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ»êºÎÀΰúÇÐȸ Á¦70Â÷ »êºÎÀΰú ¿¬¼ö°­Á ¹× ¹ßÀü¸ðÀÓ : 2024-05-17
´ÙÀ½±Û ´ëÇѺñ´¢ÀÇÇÐȸ 310ȸ Çмú´ëȸ(Àü¸³¼± ¾Ï) : 2024-05-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20694 ´ëÀü Á¦8ȸ ³»ºÐºñ ÃÊÀ½ÆÄ ¹× ±â´É°Ë»ç ¿¬¼ö°­Á : 2024-06-29 0 29 2024-05-11
20693 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 4Â÷ : 2024-06-29 0 28 2024-05-11
20692 ¼­¿ï Á¦24ȸ ´ëÇÑÀ¯Àü¼º´ë»çÁúȯÇÐȸ Á¤±âÇмú´ëȸ : 2024-06-28 0 33 2024-05-11
20691 °æ±â Á¤½Å°Ç°­ÀÇÇаú ÀÓ»ó¿¡¼­ À¯¿ëÇÑ Ä¡·á¹ý : 2024-06-26 0 38 2024-05-11
20690 ¼­¿ï (¿Â¶óÀÎ)2024 ÇѾç´ëÇб³º´¿ø È£Èí±â¾Ë·¹¸£±â ¿¬¼ö°­Á : 2024-06-22 0 29 2024-05-11
20689 ºÎ»ê °í½Å´ëÇб³º¹À½º´¿ø Á¦20ȸ °©»ó¼±¿¬¼öȸ : 2024-06-22 0 20 2024-05-11
20688 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 3Â÷ : 2024-06-22 0 7 2024-05-11
20687 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (2ÀÏÂ÷) : 2024-06-22 0 8 2024-05-11
20686 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 2 : 2024-06-21 0 17 2024-05-11
20685 ¼­¿ï ´ëÇѺÎÁ¤¸ÆÇÐȸ KHRS Annual Scientific Session 2024 (1ÀÏÂ÷) : 2024-06-21 0 11 2024-05-11
20684 ¼­¿ï Á¦50Â÷ ´ëÇѾÏÇÐȸ Çмú´ëȸ 1 : 2024-06-20 0 6 2024-05-11
20683 ¼­¿ï ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ (¿Â¶óÀÎ) ¼­¿ï°æÀÎÁöȸ 277Â÷ ¿ù·ÊÁý´ãȸ : 2024-06-18 0 21 2024-05-11
20682 ¼­¿ï 2024 °­µ¿±¸ÀÇ»çȸ Á¦3Â÷ ¿¬¼ö±³À°(¿°Áõ¼º ÀåÁúȯ,ºñ¸¸ ¾à¹° Ä¡·á ) : 2024-06-17 0 12 2024-05-11
20681 ¼­¿ï ´ëÇÑ´ç´¢º´ÇÐȸ Á¦29Â÷ ´ç´¢º´ ¿¬¼ö°­Á : 2024-06-16 0 19 2024-05-11
20680 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼ¼Æ÷º´¸®ÇÐȸ Á¦32Â÷ º´¸®Àǻ縦 À§ÇÑ ¼¼Æ÷º´¸®±³À° 2Â÷ : 2024-06-15 0 15 2024-05-11
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷